GLP-1 drugs are almost single-handedly forcing employers to reconsider how they pay for their workers’ care.
In today's Pharmalittle newsletter, drug pricing deals, a new cancer therapy approval, and more of the latest pharma ...
Caution and survival in radiopharmaceuticals, mRNA skepticism, and more biotech news from The Readout ...
The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an ...
With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the ...
A drug patent case involving Amgen is being closely watched given its potential implications for pharmaceutical patent deals ...
The mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from ...
John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of ...
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-verification ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results